Skip to main content
Premium Trial:

Request an Annual Quote

BioVeris

Premium
BioVeris announced this week that it has launched eight new products for use in life science research to measure potential immune response to protein-based therapeutics that are in development.
 
According to the company, two of the products are pharmacodynamic biomarkers, which detect human IL-2 and TNF-alpha and measure cytokine levels that may be elevated due to a drug treatment response.
 
The other six products can be used for immunogenicity testing, assay development, and hybridoma screening. “The products are composed of a panel of antibodies that are prelabeled with BioVeris’ detection label BV-TAG Plus and may be used to quantitate and characterize the following mouse antibodies: IgM, IgG, IgG1, IgG2a, IgG2b, and IgG3,” the company said in a statement.

Filed under

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.